BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31571395)

  • 1. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
    August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
    Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desensitization using pegaspargase in the era of commercially available Erwinia: A single-institution report on efficacy, cost, and resource utilization.
    Feldman K; Aaronson K; Gu T; Ige K; Southworth E; Sanchez L; Stieglitz E
    Pediatr Blood Cancer; 2024 Apr; 71(4):e30891. PubMed ID: 38311802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
    Heo YA; Syed YY; Keam SJ
    Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.
    Faschinger AM; Sessler N
    Adv Ther; 2019 Aug; 36(8):2106-2121. PubMed ID: 31140125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.
    Hoshitsuki K; Zhou Y; Miller AM; Choi JK; Swanson HD; Bhakta NH; Jeha S; Karol SE; Ribeiro RC; Rubnitz JE; Mullighan CG; Cheng C; Yang JJ; Relling MV; Pui CH; Inaba H
    Leukemia; 2023 Sep; 37(9):1782-1791. PubMed ID: 37543655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.
    Rodriguez V; Kairalla J; Salzer WL; Raetz EA; Loh ML; Carroll AJ; Heerema NA; Wood BL; Borowitz MJ; Burke MJ; Asselin BL; Devidas M; Winick NJ; Carroll WL; Hunger SP; Dreyer ZE
    J Pediatr Hematol Oncol; 2016 Aug; 38(6):409-17. PubMed ID: 27299599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and management of pegaspargase associated-toxicities (excluding coagulation abnormalities). Recommendations of the French Society of Children and Adolescent Cancers (Leukemia committee)].
    Poirée M; Neumann F; Thomas C; Simon P; Lunven AFR; Plantaz D; Doulet ST; Strullu M
    Bull Cancer; 2022 Nov; 109(11):1125-1131. PubMed ID: 35987855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.
    Kamal N; Koh C; Samala N; Fontana RJ; Stolz A; Durazo F; Hayashi PH; Phillips E; Wang T; Hoofnagle JH;
    Hepatol Int; 2019 Sep; 13(5):641-648. PubMed ID: 31392570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from premedication for pegylated asparaginase during pediatric acute lymphoblastic leukemia/lymphoma therapy: A side-by-side comparison.
    Menig S; Dinh A; Angus J; Tucker S; Leger KJ; Rushing T; Orgel E
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30716. PubMed ID: 37856184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes.
    Cassaday RD
    Best Pract Res Clin Haematol; 2023 Dec; 36(4):101519. PubMed ID: 38092476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.
    Boissel N; Sender LS
    J Adolesc Young Adult Oncol; 2015 Sep; 4(3):118-28. PubMed ID: 26421220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
    Dharia P; Swartz MD; Bernhardt MB; Chen H; Gramatges MM; Lupo PJ; Brown AL; Scheurer ME
    Leuk Lymphoma; 2022 Dec; 63(12):2948-2954. PubMed ID: 35895075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen.
    Krupa A; de Vos J; Van Eetvelde L; Teske E
    J Feline Med Surg; 2022 Aug; 24(8):e203-e213. PubMed ID: 35748790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal use of PEG-asparaginase in relapsed ALL--lessons from the ALLR3 Clinical Trial.
    Masurekar A; Fong C; Hussein A; Revesz T; Hoogerbrugge PM; Love S; Ciria C; Parker C; Krishnan S; Saha V
    Blood Cancer J; 2014 Apr; 4(4):e203. PubMed ID: 24769644
    [No Abstract]   [Full Text] [Related]  

  • 15. A comprehensive strategy to address shortage of Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Vagrecha A; Tao V; Corless R; Colon C; Redner A; Atlas M
    Expert Rev Clin Pharmacol; 2023; 16(8):763-769. PubMed ID: 37294084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
    Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors for L-asparaginase hypersensitivity in pediatric acute lymphoblastic leukemia.
    Choed-Amphai C; Khorana J; Sathitsamitphong L; Natesirinilkul R; Charoenkwan P
    Int J Hematol; 2024 Apr; 119(4):442-449. PubMed ID: 38421487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
    Fertal SA; Bradeen HA; Friesen E; Heath JL
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of acute lymphoblastic leukemia (ALL) during pregnancy using a pediatric-based protocol incorporating pegylated asparaginase.
    Jeffrey A; Presgrave P; Walsh CA; Sinn J; Kennedy D; Anazodo A; Kumar P; Osborn M; Trahair T; Bradstock K; Dalla-Pozza L; Greenwood M
    Leuk Lymphoma; 2023; 64(11):1880-1883. PubMed ID: 37516923
    [No Abstract]   [Full Text] [Related]  

  • 20. HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia.
    Lee BJ; Griffin SP; Doh J; Chan A; Ciurea SO; Jeyakumar D; Fleischman AG; Naqvi K; Pannunzio NR; O'Brien S; Kongtim P
    Eur J Haematol; 2024 Mar; 112(3):392-401. PubMed ID: 37933194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.